Issue 55, 2016, Issue in Progress

Characterization of a conglomerate-forming derivative of (±)-milnacipran and its enantiomeric resolution by preferential crystallization

Abstract

Among some derivatives of milnacipran, a last-generation antidepressive drug with useful application in the treatment of fibromyalgia, N-isobutyramide (±)-4 was identified as a conglomerate-forming compound and characterized using a binary melting diagram and X-ray analysis. Exploiting the conglomerate nature of (±)-4, its enantiomeric resolution by preferential crystallization was shown to be feasible and allowed us to obtain both enantiomers in satisfactory yield and excellent optical purity over a few cycles of entrainment.

Graphical abstract: Characterization of a conglomerate-forming derivative of (±)-milnacipran and its enantiomeric resolution by preferential crystallization

Supplementary files

Article information

Article type
Paper
Submitted
24 Mar 2016
Accepted
06 May 2016
First published
06 May 2016

RSC Adv., 2016,6, 49876-49882

Characterization of a conglomerate-forming derivative of (±)-milnacipran and its enantiomeric resolution by preferential crystallization

C. Sanfilippo, A. Forni and A. Patti, RSC Adv., 2016, 6, 49876 DOI: 10.1039/C6RA07745E

To request permission to reproduce material from this article, please go to the Copyright Clearance Center request page.

If you are an author contributing to an RSC publication, you do not need to request permission provided correct acknowledgement is given.

If you are the author of this article, you do not need to request permission to reproduce figures and diagrams provided correct acknowledgement is given. If you want to reproduce the whole article in a third-party publication (excluding your thesis/dissertation for which permission is not required) please go to the Copyright Clearance Center request page.

Read more about how to correctly acknowledge RSC content.

Social activity

Spotlight

Advertisements